📬 Melanoma Intelligence Digest — Week 2026-W37

Personalized mRNA neoantigen therapy dominates melanoma discussion as the BioNTech colorectal futility stop is used to bound INTerpath-001 to melanoma, while COMBI-I long-term OS, PIVOTAL daromun, SECOMBIT thymidine kinase, lifileucel outpatient toxicity, the COWBOY trial and imneskibart Phase 2 data all land, and a surrogate-endpoint meta-analysis of 1865 first-line patients tests ORR, PFS and TNTD against OS.

⚡ TL;DR

📄 Publications

Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy. — Individual-patient data from 1865 patients in four randomized controlled trials of single-agent nivolumab or nivolumab plus ipilimumab were used to evaluate ORR, PFS and time to next treatment or death (TNTD) as surrogates for OS

🐦 Twitter / 🦋 Bluesky

Imneskibart plus low-dose subcutaneous aldesleukin and nivolumab reports 33% ORR after progression on frontline doublet checkpoint blockade — At ASCO26, Phase 2 data for imneskibart plus low-dose subcutaneous aldesleukin and nivolumab in metastatic melanoma progressing on frontline doublet checkpoint inhibition showed a 33% objective response rate and 67% disease control rate
Macrophage IGF1-IGF1R signaling emerges as a driver of BRAF-inhibitor resistance in melanoma — BRAF inhibition increases IGF1 signaling, the IGF1-IGF1R axis shapes tumor-associated macrophage polarization and ECM organization, IGF1R-deficient macrophages render melanoma cells more sensitive to PLX4032, and macrophage IGF1R knockdown reduces tumor growth in vivo
COWBOY: BRAF/MEK induction before ipilimumab-nivolumab underperforms upfront immunotherapy in high-LDH BRAF V600E/K melanoma — COWBOY examined induction vemurafenib plus cobimetinib prior to ipilimumab-nivolumab in patients with BRAF V600E/K-mutated melanoma and elevated LDH versus upfront immunotherapy
Lifileucel outpatient toxicity after hospital discharge: low rates of new grade 3+ TRAEs and readmission — Incidence of new grade 3 or higher treatment-related adverse events and readmissions is low in melanoma patients discharged after tumor-infiltrating lymphocyte therapy with lifileucel

Full details below ↓

📄 What's Being Published

Manuscripts:

Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy. — Squifflet Pierre et al., J Immunother Cancer

Individual-patient data from 1865 patients enrolled in four randomized controlled trials of single-agent nivolumab or nivolumab plus ipilimumab were used to evaluate ORR, PFS, and time to next treatment or death (TNTD) as candidate surrogates for OS. For ORR, the individual-level OR of survival was 12.29 (95% CI 9.78 to 14.80) and the trial-level R² was 0.62 (95% CI 0 to 1.00); for PFS, the individual-level ρ was 0.72 (95% CI 0.70 to 0.73) with trial-level R² 0.73 (95% CI 0.27 to 1.00); and for TNTD, the individual-level ρ was 0.77 (95% CI 0.76 to 0.78) with trial-level R² 0.77 (95% CI 0.37 to 1.00). At the trial level, the key requirement for surrogate validation, all three candidate endpoints demonstrated only moderate predictive ability for OS, while ORR exhibited a strong individual-level correlation with OS.

Clinical bottom line: In first-line metastatic melanoma treated with nivolumab-based regimens, ORR tracks OS tightly for the individual patient but none of ORR, PFS, or TNTD reaches more than moderate trial-level predictive ability, so registration decisions built on these endpoints still carry real uncertainty about survival.

Read full article →

🗂 Every paper considered this week, including the ones that didn’t make it →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

Imneskibart plus low-dose subcutaneous aldesleukin and nivolumab reports 33% ORR after progression on frontline doublet checkpoint blockade

Phase 2 data presented at ASCO26 for imneskibart combined with low-dose subcutaneous aldesleukin and nivolumab in metastatic melanoma progressing on frontline doublet checkpoint inhibition showed a 33% objective response rate and 67% disease control rate in a setting where options narrow quickly. For context in the same post-anti-PD-1 refractory space, vusolimogene plus nivolumab was approved on an ORR of 24.2% with a median duration of response of 14.1 months. The open question is how these two approaches should be positioned relative to each other, and which patients are best suited to an IL-2-based combination versus the newly approved oncolytic option.

Discussed by: @AulosBioscience, @OncBrothers

→ View representative tweet

Macrophage IGF1-IGF1R signaling emerges as a driver of BRAF-inhibitor resistance in melanoma

BRAF inhibition increases IGF1 signaling, and the IGF1–IGF1R axis shapes tumor-associated macrophage polarization and ECM organization; IGF1R-deficient macrophages render melanoma cells more sensitive to PLX4032, and macrophage IGF1R knockdown reduces tumor growth in vivo, placing the tumor microenvironment at the center of this resistance mechanism. A separate report shows that combining lymphodepleting chemotherapy with dual immune checkpoint blockade enhances clonal expansion of effector CD8+ TILs, delays tumor growth, and improves survival. Together these data press the question of whether the tumor microenvironment, rather than the melanoma cell itself, is where the next generation of BRAF-inhibitor resistance strategies should be directed.

Discussed by: @MarioBalsaMD, @SCIDirector

→ View representative tweet

COWBOY: BRAF/MEK induction before ipilimumab-nivolumab underperforms upfront immunotherapy in high-LDH BRAF V600E/K melanoma

The COWBOY trial examined induction vemurafenib plus cobimetinib prior to ipilimumab-nivolumab in patients with BRAF V600E/K-mutated melanoma and elevated LDH versus upfront immunotherapy, but was terminated prematurely due to slow patient accrual. Analysis of the over 70 randomized patients indicates more favorable outcomes in the upfront immunotherapy group. Whether an underpowered, prematurely closed randomized trial is sufficient to retire targeted-therapy induction ahead of ipilimumab-nivolumab in this high-LDH BRAF-mutant population remains contested.

Discussed by: @VJOncology, @ASCOPost

→ View representative tweet

Lifileucel outpatient toxicity after hospital discharge: low rates of new grade 3+ TRAEs and readmission

Published in JCO Oncology Practice, the analysis titled "Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma" reports that incidence of new grade 3 or higher treatment-related adverse events and readmissions is low in patients with melanoma discharged after tumor-infiltrating lymphocyte therapy with lifileucel. These post-discharge safety data bear directly on whether more of the lifileucel recovery period can be delivered outside a TIL-experienced inpatient center, a question with practical access and resource implications for programs considering adoption.

Discussed by: @CancerTherAdvsr, @JCOOP_ASCO

→ View representative tweet

🔥 Top Ranked Tweets

Neeraj Agarwal, MD, FASCO @neerajaiims

RT @OncoAlert: This week's OncoAlert 🚨 Newsletter is packed with practice-changing data:
REGISTER TO GET IT 👉 https://t.co/NhtuRoIyO3

NOW OUT!
✅️ FDA 🇺🇸 approves daraxonrasib — first-in-class RAS inhibitor for metastatic #PancreaticCancer
✅️FDA approves zanidatamab-hrii + tislelizumab-jsgr for HER2+ gastric/GEJ/esophageal cancer
✅️Merck & Moderna's INTerpath-001 hits its endpoints — mRNA neoantigen therapy + pembrolizumab in resected #melanoma
✅️5-year KEYNOTE-671 data confirms durable benefit of perioperative pembrolizumab in resectable NSCLC #LungCancer
✅️Dose-escalated radiotherapy (80 Gy) improves 10-year PFS in high-risk #ProstateCancer (GETUG AFU 18)

...and more, curated by practicing oncologists — for colleagues, by colleagues.

Get it in your inbox every week!

@matteolambe
@aftimosp
@E_de_Azambuja
@DrSGraff
@ErikaHamilton9
@double_whammied
@maryam_lustberg
@raalbany
@hoperugo
@stolaney1
@LoiSher
@JaniceTNBCmets
@montypal
@DrDanielHeng
@apolo_andrea
@DrChoueiri
@PGrivasMDPhD
@TiansterZhang
@neerajaiims
@amerseburger
@sonpavde
@drenriquegrande
@tompowles1
@cdanicas
@nataliagandur
@realbowtiedoc
@Onco_Cifu88
@scocmem
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@Erman_Akkus
@MarioBalsaMD
@DrMirallas
@GIMedOnc
@UOzkerim
@DrRishabhOnco
@PaulJiL
@DaisukeKotani
@DraMartinezLago
@p_ciracimd
@BenWestphalen
@CentralParkWMD
@graokane
@amandaNizamMD
@DrVilmaPBarcia

🔖 2 ❤️ 31 🔁 16 👁 7,549